ArticleDusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi2026
Evaluation of brexpiprazole as adjunctive therapy in treatment-resistant depression: Real-world data.
Article in Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Brexpiprazole (BRX) is an antipsychotic used as an adjunctive agent in the treatment of major depressive disorder. We aimed to evaluate the effectiveness of BRX in treatment-resistant depression (TRD). Method: This study was conducted between May 1, 2024 and January 1, 2025. Medical records of patients who were started on BRX as adjunctive treatment for TRD were retrospectively reviewed. Patient files containing sociodemographic data and scores from the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Global Assessment Scale (GAS) were included in the analysis. Results: A total of 30 patients were included in the study. The mean age was 32.50±11.38 years (range: 18-63), and 63.3% (n=19) were female. The median BRX dose was 2 mg/day. Of the 30 patients, 20 (66.7%) continued treatment regularly. Among those who discontinued treatment, three patients stopped due to akathisia, two due to sedation, and two due to an urgent need for electroconvulsive therapy. For the 20 patients who continued treatment, scale scores were reassessed during follow-up visits between weeks 4 and 8. A significant improvement was observed in both BDI scores (32.05±8.96 vs. 12.45±9.74; p<0.001) and BAI scores (28.00±10.07 vs. 12.75±10.83; p=0.001) after treatment. Meanwhile, no significant change was observed in body weight (73.05±20.93 kg vs. 75.30±20.32 kg; p=0.123). Among patients whose GAS scores indicated moderate functioning before BRX treatment, 80% (n=16) achieved good functioning after treatment. Conclusion: BRX may be an effective adjunctive treatment option for patients with TRD, with potential benefits for anxiety symptoms and overall functioning. Although some patients experienced weight gain, this effect did not appear to be clinically significant in our sample.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.